William Blair Maintains Outperform On BioDelivery Sciences


William Blair today maintained an Outperform rating on BioDelivery Sciences (BDSI) with $23.00 price target, which is derived through a net present value analysis of the company’s main programs in opioid dependence and chronic pain.

The firm analyst Tim Lugo said, “With an enterprise value of under $500 million, despite the recent appreciation, and a significant opportunity for Bunavail and BEMA buprenorphine, two products that could exceed $750 million in peak-year sales, BioDelivery Sciences remains one of our best small-cap ideas”.

According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, analyst Tim Lugo, who covers BDSI, has a one-year average return of -8.8% and a 20% success rate.

BDSI Chart

 

 

 

 

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts